<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069120</url>
  </required_header>
  <id_info>
    <org_study_id>ZPU-307</org_study_id>
    <nct_id>NCT01069120</nct_id>
  </id_info>
  <brief_title>Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids</brief_title>
  <official_title>A Phase III Multicenter Extension Study Evaluating the Safety of 25 and 50 mg Proellex® in the Treatment of Women Who Have Completed ZPU-301, ZPU-302, ZPU-303, or ZPU-304</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and efficacy study of 25 and 50 mg doses of Proellex
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is intended to provide more abundant safety and efficacy data of both the 25 and 50
      mg doses of Proellex than ZPU-301, ZPU-302, ZPU-303 and ZPU-304 alone.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Repros stopped study due to safety and FDA placed study on hold
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Assess the Incidence of Adverse Events (AE) and Serious Adverse Events (SAEs)</measure>
    <time_frame>During two 4 month treatment periods</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Uterine Fibroids</condition>
  <arm_group>
    <arm_group_label>50 mg Proellex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2, 25 mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25 mg Proellex®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1, 25 mg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex</intervention_name>
    <description>2, 25 mg capsules once per day</description>
    <arm_group_label>50 mg Proellex®</arm_group_label>
    <other_name>CDB-4124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proellex</intervention_name>
    <description>1, 25 mg capsule once per day</description>
    <arm_group_label>25 mg Proellex®</arm_group_label>
    <other_name>CDB-4124</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 1 uterine fibroid must be identifiable and measurable by Transvaginal
             Ultrasound (TVU)

          -  Subject has a menstrual cycle lasting from 20 to 40 days.

          -  Subject must have satisfactorily completed all study visits from the previous study in
             which she participated: ZPU-301, ZPU-302, ZPU-303, or ZPU-304

        Exclusion Criteria:

          -  Subjects who have not participated in 1 of the previous Repros studies: ZPU-301,
             ZPU-302, ZPU-303, or ZPU-304.

          -  Subjects who met treatment stopping rules as per the DILI Guidance requirements while
             participating in ZPU-301, ZPU-302, ZPU-303, or ZPU-304
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre vanAS, PhD, Md</last_name>
    <role>Study Director</role>
    <affiliation>Repros Therapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Insignia Clinical Research (Tampa Bay Women's Center)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances in Health Inc</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Hospital of Texas, Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <results_first_submitted>June 25, 2014</results_first_submitted>
  <results_first_submitted_qc>August 5, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 21, 2014</results_first_posted>
  <last_update_submitted>August 5, 2014</last_update_submitted>
  <last_update_submitted_qc>August 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine Fibroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Proellex®</title>
          <description>25 or 50 mg capsules once per day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study prematurely terminated</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study prematurely terminated</population>
      <group_list>
        <group group_id="B1">
          <title>50 mg Proellex®</title>
          <description>Proellex: 2, 25 mg capsules once per day</description>
        </group>
        <group group_id="B2">
          <title>25 mg Proellex®</title>
          <description>Proellex: 1, 25 mg capsule once per day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Assess the Incidence of Adverse Events (AE) and Serious Adverse Events (SAEs)</title>
        <time_frame>During two 4 month treatment periods</time_frame>
        <group_list>
          <group group_id="O1">
            <title>50 mg Proellex®</title>
            <description>Proellex: 2, 25 mg capsules once per day</description>
          </group>
          <group group_id="O2">
            <title>25 mg Proellex®</title>
            <description>Proellex: 1, 25 mg capsule once per day</description>
          </group>
        </group_list>
        <measure>
          <title>To Assess the Incidence of Adverse Events (AE) and Serious Adverse Events (SAEs)</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>No adverse events data is available.</desc>
      <group_list>
        <group group_id="E1">
          <title>50 mg Proellex®</title>
          <description>Proellex: 2, 25 mg capsules once per day</description>
        </group>
        <group group_id="E2">
          <title>25 mg Proellex®</title>
          <description>Proellex: 1, 25 mg capsule once per day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication, Investigator shall submit to the Sponsor a copy of any proposed publication. Sponsor shall have sixty (60) days to review the proposed publication for possible disclosure of Sponsor’s Confidential Information and, upon request of Sponsor, Investigator shall delete any of Sponsor’s Confidential Information or withhold submission of such publication to allow Sponsor to protect its intellectual property rights</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was prematurely terminated for safety reasons (Proellex studies were put on clinical hold due to liver toxicity). Sponsor was unable to pay vendor, and was therefore not provided with any study data.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Jennifer Wike</name_or_title>
      <organization>Repros Therapeutics Inc.</organization>
      <phone>2817193402</phone>
      <email>jwike@reprosrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

